Mainstay Medical Announces the Publication of “Effect of Restorative Neurostimulation on Major Drivers of Chronic Low Back Pain Economic Impact"
Mainstay Medical Holdings plc today announced the publication of “Effect of Restorative Neurostimulation on Major Drivers of Chronic Low Back Pain Economic Impact", in the journal Neurosurgery. The paper contains a review of patients from the pivotal ReActiv8-B study, and the effect of ReActiv8 restorative neurostimulation on known drivers of direct and indirect long-term health care costs. High impact pain, defined as pain present on most days for six months or more with substantial restrictions to participation in work, social, and self-care activities, has been linked to much higher direct healthcare costs per year than moderate or low impact pain states.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230301005280/en/
(Graphic: Business Wire)
The results of this study showed that patients overwhelmingly converted from a high impact pain state to a low impact pain state after two years of ReActiv8 therapy. In a completer analysis of those patients available at 2 years and having work data (n=146), 103 (70.5%) were high impact pain patients at baseline. After 2 years, 15 (10.3%) patients remained in the high impact pain state, while 124 patients (85%) were in the low impact pain category.
Chris Shaffrey, Chief of Spinal Surgery at Duke University, added: “It’s incredibly impressive to see a novel therapy that’s able to successfully treat chronic mechanical low back pain not only clinically, but also in a way that has a positive economic impact on the healthcare system and the employers of these patients. Physicians across multiple specialties should strongly consider providing ReActiv8 for their patients earlier in their care continuum based on these results”.
Chris Gilligan, Director of the Brigham and Women’s Spine Center at Brigham and Women’s Hospital, assistant professor of Anesthesia at Harvard Medical School (Boston, USA), and Principal Investigator of the study, concluded: “Restorative neurostimulation continues to prove long-term clinical benefits, but until now, we were unsure of the economic impact. This publication is the first step in proving how ReActiv8 can take high impact pain patients, costing a significant amount of annual direct and indirect healthcare costs, and not only improve their pain, disability, and quality of life, but also reduce healthcare costs in the process”.
In looking at indirect drivers of economic impact, this study examined presenteeism, the reduced ability to perform occupational tasks because of back pain, as well as absenteeism, the number of days missed from work because of low back pain. At baseline, approximately 50% of patients experienced significant restrictions on work participation resulting in notable presenteeism and/or absenteeism, while less than 50% of patients reported no work problems. After two years, over 80% of patients reported no impact or only minor impact to their work participation due to low back pain. It was especially noteworthy that 88% of patients were not missing any days off work due to low back pain after 2 years.
The pain impact data from this publication suggests the potential for a significant reduction in direct and indirect healthcare utilization levels and costs for patients using ReActiv8. In addition, the durability of the clinically meaningful improvements in pain and function demonstrated in this study are consistent with a restorative mechanism of action, which suggests that over the long term, these improvements in pain impact health states will be maintained.
Jason Hannon, Chief Executive Officer of Mainstay Medical, stated: “The ReActiv8-B study data we have previously published has shown durable and substantial improvements in patients’ pain and disability outcomes. This new publication shows that ReActiv8 restorative neurostimulation therapy has the potential to provide significant reductions in healthcare costs related to these heavily-burdened patients, which will be important as we continue to discuss potential coverage for the therapy with insurers”.
ReActiv8 is an implantable medical device designed to treat adults with intractable chronic low back pain (CLBP) associated with multifidus muscle dysfunction. Multifidus muscle dysfunction may be evidenced by imaging or physiological testing in adults who have failed therapy, including pain medications and physical therapy, and who are not candidates for spine surgery. ReActiv8 has received regulatory approval in several geographic areas, and is commercially available in the European Economic Area, Australia, the UK, and the US.
About Mainstay Medical
Mainstay Medical is a medical device company focused on commercializing its innovative implantable Restorative Neurostimulation™ system, ReActiv8®, for people with disabling mechanical CLBP. Mainstay Medical is headquartered in Dublin, Ireland and has subsidiaries operating in Ireland, the United States, Australia, Germany and the Netherlands.
Further information can be found at www.mainstaymedical.com.
All statements in this announcement other than statements of historical fact are, or may be deemed to be, forward-looking statements. These forward-looking statements may include, without limitation, statements regarding the company’s intentions, beliefs or current expectations concerning, among other things, the ability of ReActiv8 to reduce healthcare costs, the company’s commercial efforts and performance, financial position, financing strategies, product design and development, regulatory applications and approvals, and reimbursement arrangements.
Forward-looking statements involve risk and uncertainty and are not guarantees of future performance. Actual results may differ materially from those described in, or suggested by, the forward-looking statements. A number of factors could cause results and developments to differ materially from those expressed or implied by the forward-looking statements herein, including, without limitation, the risks and uncertainties included in the company’s Annual Report for the year ended 31 December 2021, which should be read in conjunction with the company’s public disclosures (available on the company’s website (www.mainstaymedical.com)). The forward-looking statements herein speak only as of the date of this announcement.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230301005280/en/
PR and IR Enquiries:
LifeSci Advisors, LLC
Tel: + 1 (212) 915-2578
FTI Consulting (for Ireland)
Jonathan Neilan or Patrick Berkery
Tel. : +353 1 765 0886
About Business Wire
24 Martin Lane
EC4R 0DR London
+44 20 7626 1982http://www.businesswire.co.uk
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Stilla Ruby Chip and naica ® system 21 CFR Part 11 compliance enable full automation of digital PCR testing for clinically-oriented applications20.3.2023 16:48:00 CET | Press release
Stilla Technologies, the multiplex digital PCR company, has recently introduced the Ruby Chip, the industry’s first ‘load-and-go’ consumable for digital PCR, optimized for its naica® system. The naica® system, which now supports 21 CFR Part 11 regulatory compliance, is part of a fully-automated sample-to-results workflow – the first of its kind for digital PCR. This platform serves the growing throughput and regulatory requirements of many clinically-oriented applications, such as in cell and gene therapy development and quality control or for liquid biopsy applications for the detection of circulating tumor DNA (ctDNA). With adjustable throughput of up to 96 samples processing capability in under three hours, the Ruby Chip is designed with standard SBS plate spacing compatible with multichannel pipettes for manual loading and can be easily integrated with common liquid handling robots. A key feature of the Ruby Chip is that it comes ready-to-use and preloaded with sealed chambers, ena
LambdaTest improves its Selenium automation testing experience with the addition of its AI-powered integrated test intelligence20.3.2023 15:30:00 CET | Press release
LambdaTest, an intelligent omnichannel digital experience testing cloud platform, has announced the addition of advanced AI-powered test intelligence features to its Selenium testing cloud offering. With this latest development, LambdaTest will now enable enterprises with deeper insights into their test execution process and help them better streamline their quality assurance process. LambdaTest has been constantly working on enhancing its Selenium automation testing cloud and the test intelligence feature is the latest addition to the list. Over the last quarter, LambdaTest has added features like support for all Selenium 4 versions, including support for BiDi protocol, enhanced low-latency live streaming of test execution for faster test feedback, and the ability to group tests by tags for better manageability. Just last month, LambdaTest added Selenium tracing that allows users to visualize each command flow and each test error along with its telemetry data. All these features combi
FlexTrade Hires Senior Sell-Side OMS Specialist to Drive Growth in EMEA Region20.3.2023 15:30:00 CET | Press release
FlexTrade Systems (@FlexTrade), a global leader in multi-asset order and execution management systems, announces the appointment of Rajiv Shah as Head of Sales in EMEA for its sell-side OEMS, FlexOMS. FlexOMS, the flagship OMS platform within FlexTrade's suite of sell-side solutions, is designed to boost trading efficiency by simplifying the complexities of today's trading workflows. The open-architecture trading solution supports high-touch and low-touch businesses by providing a unified multi-asset platform across cash, program trading, futures & options, ETF, swaps, fixed income, and foreign exchange workflows. In this newly created role, Rajiv will drive FlexTrade's business strategy and growth of the solutions to trading desks within EMEA. Rajiv brings over 30 years of experience in financial technology with a proven track record in designing and executing sales and business growth strategies across the front and middle-office trading space within enterprise-grade software firms.
CSG’s State of the Customer Experience 2023 Report Uncovers Trending Areas for First-Class CX Strategy20.3.2023 14:30:00 CET | Press release
CSG® (NASDAQ: CSGS), the leader in innovative customer experience, revenue management and payments solutions that make ordinary customer experiences extraordinary, today released The State of the Customer Experience 2023 Report. With data from over 12 billion global customer journey interactions and 710 million supported end consumers this year, CSG found that business leaders are feeling the need for speed to accelerate digital customer experiences (CX) but need help kickstarting their CX journey. “This year’s findings illustrate a clear runway for the future of customer experience,” said Mark Smith, Senior Vice President of Customer Experience at CSG. “Brand leaders are more eager than ever to board the CX plane but understand they first need a clear flight plan to get to their destination. This all starts with the basics – understand your customer, receive their trust by integrating security, and maintain the quality of non-digital experiences for customers who aren’t ready for the
RevBits Privileged Access Management® Wins Gold in the 2023 Cybersecurity Excellence Awards20.3.2023 14:15:00 CET | Press release
RevBits today announced that it was recognized as a winner in the Privileged Access Management category for its PAM solution by the 2023 Cybersecurity Excellence Awards®. The review process judges the world's top providers by their organizational size, performance, technology, products, and leadership. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230320005003/en/ (Graphic: Business Wire) RevBits is pleased to be the recipient of three awards in the following categories: Gold – Privileged Access Management / North AmericaRevBits Privileged Access Management "It is extremely gratifying to see that in a very competitive environment, we are recognized for the innovation we bring," said David Schiffer, CEO. "To share the winner's circle with top market performers is wonderful and is only achievable thanks to the great talent of our co-founder and CTO Mucteba Celik. We consider our PAM solution to be "the Ultimate Replacement So